Sands Capital Alternatives, LLC
ARLINGTON, VA · CIK 1846444 · 13F filing filed 2023-08-15
SEC-registered investment adviser since 2011 · limited liability company
- Assets managed$5.4bn
- Staff182 · 66 in investment roles
- Main clients (by assets)Private funds 97%, Pension plans 3%
- Private funds34 · $3.7bn gross assets
- Websitesandscapital.com
- Form ADV · 2026-07-28SEC adviser record
- Legal entitySANDS CAPITAL ALTERNATIVES, LLC (US)
- Kindhedge funds, private equity, venture, futures, wealth
- Others nearbyArlington, VA, London, San Francisco, CA, New York, NY, Charlottesville, VA, Singapore
- FamilySands Capital Alternatives, LLC · 2 related pages
As an employer
- Offices in3 countries
- Private fundsprivate equity 23, venture capital 11
Where they work
Offices
From Form ADV: the main office and the other offices where it does advisory work (at most the 25 largest), with the people doing investment work at each. “About” is worked out: the firm's investment staff less its other offices. Each city links to the other managers there.
| City | People |
|---|---|
| Arlington, VA (main office)United States | about 60 |
| Fitzrovia LondonUnited Kingdom | 2 |
| San Francisco, CAUnited States | 2 |
| New York City, NYUnited States | 1 |
| San Juan, PRUnited States | 1 |
| SingaporeSingapore |
Map: places from GeoNames (CC BY 4.0), outlines from Natural Earth.
Holdings, Q2 2023
The small lines show how much was held over the last 4 quarters (adjusted for stock splits).
| Security | Value | Change |
|---|---|---|
| NU HLDGS LTD NU | $72.2m21.36% | Reduced -3.8k |
| UIPATH INC PATH | $50.8m15.03% | Reduced -750.0k |
| DOORDASH INC DASH | $46.1m13.64% | Unchanged |
| SAMSARA INC IOT | $42.8m12.65% | Reduced -751.3k |
| SNOWFLAKE INC SNOW | $38.0m11.23% | Added +173 |
| 10X GENOMICS INC TXG | $26.9m7.96% | Unchanged |
| ACRIVON THERAPEUTICS INC ACRV | $21.4m6.34% | Unchanged |
| ACUMEN PHARMACEUTICALS INC ABOS | $16.4m4.86% | Unchanged |
| OLINK HLDG AB SPONSORED ADS | $13.2m3.91% | Unchanged |
| TARSUS PHARMACEUTICALS INC TARS | $4.7m1.39% | Unchanged |
| SPRUCE BIOSCIENCES INC COM | $1.7m0.50% | Unchanged |
| 908 DEVICES INC MASS | $1.6m0.48% | Reduced -89.2k |
| CANDEL THERAPEUTICS INC CADL | $1.0m0.30% | Unchanged |
| TAYSHA GENE THERAPIES INC TSHA | $478.4k0.14% | Unchanged |
| COUPANG INC CPNG | $146.8k0.04% | Added +1.5k |
| TOAST INC TOST | $141.9k0.04% | Added +1.8k |
| DATADOG INC DDOG | $134.4k0.04% | Unchanged |
| CROWDSTRIKE HLDGS INC CRWD | $109.3k0.03% | Reduced -120 |
| ABSCI CORPORATION ABSI | $87.9k0.03% | Unchanged |
| CONFLUENT INC CFLT | $47.8k0.01% | Unchanged |
| GITLAB INC GTLB | $33.6k0.01% | Unchanged |
Sold out since Q1 2023
| Security | Value then |
|---|---|
| DICE THERAPEUTICS INC | $78.8m2.7m shares |
| KARUNA THERAPEUTICS INC | $10.7m58.9k shares |
Stakes above 5%
Companies where this manager has reported owning more than 5% of a class of shares, on Schedule 13D (may seek influence) or 13G (passive): its latest filing for each, from 19 Dec 2024 on.
| Company | Stake |
|---|---|
| ACUMEN PHARMACEUTICALS INC ABOS · 13G · filed 2025-08-13 | 5.6%≈ $9.1m |